MX2015011387A - Indolo[2,3-b]quinoxalina antiviral. - Google Patents

Indolo[2,3-b]quinoxalina antiviral.

Info

Publication number
MX2015011387A
MX2015011387A MX2015011387A MX2015011387A MX2015011387A MX 2015011387 A MX2015011387 A MX 2015011387A MX 2015011387 A MX2015011387 A MX 2015011387A MX 2015011387 A MX2015011387 A MX 2015011387A MX 2015011387 A MX2015011387 A MX 2015011387A
Authority
MX
Mexico
Prior art keywords
indolo
quinoxaline
antiviral
compound
formula
Prior art date
Application number
MX2015011387A
Other languages
English (en)
Inventor
Mohammed Homman
Ngarita Kingi
Jan Bergman
Robert Berg
Original Assignee
Vironova Herpes Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vironova Herpes Ab filed Critical Vironova Herpes Ab
Publication of MX2015011387A publication Critical patent/MX2015011387A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporciona un compuesto de fórmula (I) útil en el tratamiento de infección viral por herpes. Se proporciona una composición farmacéutica que comprende el compuesto de fórmula (I).
MX2015011387A 2013-03-15 2014-03-14 Indolo[2,3-b]quinoxalina antiviral. MX2015011387A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361788867P 2013-03-15 2013-03-15
PCT/EP2014/055178 WO2014140321A1 (en) 2013-03-15 2014-03-14 Antiviral indolo[2,3-b]quinoxaline

Publications (1)

Publication Number Publication Date
MX2015011387A true MX2015011387A (es) 2016-06-10

Family

ID=50280403

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011387A MX2015011387A (es) 2013-03-15 2014-03-14 Indolo[2,3-b]quinoxalina antiviral.

Country Status (16)

Country Link
US (1) US20160031889A1 (es)
EP (1) EP2970292A1 (es)
JP (1) JP2016510798A (es)
KR (1) KR20150130463A (es)
CN (1) CN105102459A (es)
AU (1) AU2014230133A1 (es)
BR (1) BR112015022134A2 (es)
CA (1) CA2904468A1 (es)
CL (1) CL2015002730A1 (es)
EA (1) EA201500942A1 (es)
HK (1) HK1220196A1 (es)
IL (1) IL241364A0 (es)
MX (1) MX2015011387A (es)
SG (1) SG11201507310VA (es)
WO (1) WO2014140321A1 (es)
ZA (1) ZA201507151B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021250196A1 (en) * 2020-06-10 2021-12-16 Cyxone Ab New use of rabeximod
WO2022002898A1 (en) * 2020-06-29 2022-01-06 Vironova Medical Ab 6h-indolo(2,3-b)quinoxaline derivatives useful in therapy in particular in a virus infection
AU2021344650A1 (en) 2020-09-21 2023-05-18 Vironova Medical Ab Thionoester-derivative of rabeximod for the treatment of inflammatory and autoimmune disorders
US11643415B1 (en) * 2021-12-09 2023-05-09 Cyxone Ab Rabeximod compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE527639C2 (sv) * 2004-06-17 2006-05-02 Oxypharma Ab Alkylsubstituerade indolokinoxaliner

Also Published As

Publication number Publication date
SG11201507310VA (en) 2015-10-29
ZA201507151B (en) 2017-01-25
BR112015022134A2 (pt) 2017-07-18
CN105102459A (zh) 2015-11-25
KR20150130463A (ko) 2015-11-23
AU2014230133A1 (en) 2015-11-05
WO2014140321A1 (en) 2014-09-18
EA201500942A1 (ru) 2016-03-31
HK1220196A1 (zh) 2017-04-28
CA2904468A1 (en) 2014-09-18
EP2970292A1 (en) 2016-01-20
US20160031889A1 (en) 2016-02-04
IL241364A0 (en) 2015-11-30
CL2015002730A1 (es) 2016-07-01
JP2016510798A (ja) 2016-04-11

Similar Documents

Publication Publication Date Title
IL264402B (en) History of pyrrolo(2,3–d)pyrimidine for the treatment of viral infections and other diseases
HRP20180771T1 (hr) Derivati pirolo[3,2-d]pirimidina za liječenje virusnih infekcija i drugih bolesti
MX2019009100A (es) Nuevos derivados de triazolo[4,5-d]pirimidina.
MX2017004652A (es) Novedoso derivado de 5,6-dihidro-4h-benzo[b]tieno-[2,3-d]azepina.
NZ705040A (en) Fused pyrimidines as inhibitors of p97 complex
PH12015501993A1 (en) Pyrazole-amide compound and medicinal uses therefor
WO2015110491A3 (en) Pyrazolo[1,5-a]pyrimidines as antiviral compounds
PH12015502118A1 (en) Pyridin-4-yl derivatives
PH12015502409B1 (en) Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists
MX2015000362A (es) Benzo(b)-azepin-2-onas antiproliferativas.
PH12015502178A1 (en) Pyridinylpyrazoloquinoline compound
MX2018013133A (es) Compuesto de pirazolo[1,5-a]pirimidina.
MX2015011387A (es) Indolo[2,3-b]quinoxalina antiviral.
PH12015500399A1 (en) Azaindolines
SI2766367T1 (sl) 4-amino-3-fenilamino-6-fenilpirazol(3,4-D)primidinski derivati za zdravljenje virusnih okužb, zlasti pikornavirusnih okužb